Skip to main content
International Journal of Molecular Sciences logoLink to International Journal of Molecular Sciences
. 2015 Mar 20;16(3):6464–6495. doi: 10.3390/ijms16036464

High-Resolution Chromosome Ideogram Representation of Currently Recognized Genes for Autism Spectrum Disorders

Merlin G Butler 1,*, Syed K Rafi 1,, Ann M Manzardo 1,
Editor: William Chi-shing Cho1
PMCID: PMC4394543  PMID: 25803107

Abstract

Recently, autism-related research has focused on the identification of various genes and disturbed pathways causing the genetically heterogeneous group of autism spectrum disorders (ASD). The list of autism-related genes has significantly increased due to better awareness with advances in genetic technology and expanding searchable genomic databases. We compiled a master list of known and clinically relevant autism spectrum disorder genes identified with supporting evidence from peer-reviewed medical literature sources by searching key words related to autism and genetics and from authoritative autism-related public access websites, such as the Simons Foundation Autism Research Institute autism genomic database dedicated to gene discovery and characterization. Our list consists of 792 genes arranged in alphabetical order in tabular form with gene symbols placed on high-resolution human chromosome ideograms, thereby enabling clinical and laboratory geneticists and genetic counsellors to access convenient visual images of the location and distribution of ASD genes. Meaningful correlations of the observed phenotype in patients with suspected/confirmed ASD gene(s) at the chromosome region or breakpoint band site can be made to inform diagnosis and gene-based personalized care and provide genetic counselling for families.

Keywords: high-resolution chromosome ideograms, autism, genetic evidence, autism spectrum disorders (ASD), ASD genes

1. Introduction

Classical autism or autistic disorder is common, with developmental difficulties noted by three years of age. It belongs to a group of heterogeneous conditions known as autism spectrum disorders (ASDs) with significant impairments in verbal and non-verbal communication and social interactions with restricted repetitive behaviors, specifically in movements and interests [1,2,3]. Other symptoms include lack of eye contact or focus, sleep disturbances and tactile defensiveness beginning at an early age. Several validated rating scales are used at a young age to help establish the diagnosis, including the autism diagnostic observation schedule (ADOS) and the autism diagnostic interview-revised (ADI-R) supported by pertinent medical history and clinical findings [4,5,6]. ASD affects about 1% of children in the general U.S. population with a 4:1 male to female ratio, usually without congenital anomalies or growth retardation [7,8].

Autism was first used as a term by Kanner in 1943 when describing a group of children lacking the ability to establish interpersonal contact and communication [9]. About one-fourth of children with autism are diagnosed by 2–3 years of age and show regression of skills in about 30% of cases. About 60% of ASD subjects show intellectual disabilities at a young age [10,11]. When comparing the prevalence of health disorders involving the central nervous system, autism ranks higher than epilepsy (6.5 cases per 1000), brain paralysis or dementia (2.5 cases/1000 for each) and Parkinson disease (two cases per 1000); genetic factors are related to many of these disorders [12,13]. Autism also occurs more commonly than congenital malformations in the general population, but dysmorphic findings are present in about 25% of children with autism. Microcephaly is seen in about 10% of cases, but macrocephaly is documented with larger frontal and smaller occipital lobes in about 20% of children with autism. Those with autism and extreme macrocephaly are at a greater risk to have PTEN tumor suppressor gene mutations [14], while another autism-related gene (CHD8) can also lead to macrocephaly and autism [15].

Autism is due to a wide range of genetic abnormalities, as well as non-genetic causes, including the environment, environmental and gene interaction (epigenetics) and metabolic disturbances (e.g., mitochondrial dysfunction), with the recurrence risk dependent on the family history and presence or absence of dysmorphic features. Candidate genes for ASD are identified by different means, including cytogenetic abnormalities (i.e., translocations at chromosome breakpoints or deletions (e.g., the 22q11.2 deletion) indicating the location or loss of specific genes) in individuals with ASD along with overlapping linkage and functional data related to the clinical presentation, with certain chromosome regions identified by genetic linkage using DNA markers that co-inherit with the specific phenotype [16,17]. A representative example for such an occurrence is the proto-oncogene (MET) involved in pathways related to neuronal development [18] and found to be linked to the chromosome 7q31 band, where this gene is located. Decreased activity of the gene promoter was recognized when specific single nucleotide polymorphisms (SNPs) were present in this region by linkage studies. However, genetic linkage studies have received only limited success in the study of the genetics of autism. On the other hand, chromosomal microarray analysis using DNA probes disturbed across the genome can be used to detect chromosomal abnormalities at >100-times smaller than seen in high-resolution chromosome studies. Microarray studies have also become the first tier of genetic testing for this patient population and are recommended for all ASD patients [19]. Greater than 20% of studied patients with microarray analysis are found to have submicroscopic deletions or duplications in the genome containing genes that play a role in causing autism [20,21]. Identification of causative mutations is important to guide treatment selection and to manage medical co-morbidities, such as risks for seizures, developmental regression or for cancer (e.g., the PTEN gene).

Routine cytogenetic studies have shown abnormalities of chromosomes 2, 3, 4, 5, 7, 8, 11, 13, 15, 16, 17, 19, 22 and X, including deletions, duplications, translocations and inversions involving specific chromosome regions where known or candidate genes for ASD are located [22]. These studies further support the role of genetic factors in the causation of this common neurodevelopment disorder. Specifically, cytogenetic abnormalities involving the 15q11–q13 region are found in at least 1% of individuals with ASD and include CYFIP1, GABRB3 and UBE3A genes in this chromosome region [23] and most recently the 15q11.2 BP1-BP2 microdeletion (Burnside-Butler) syndrome [24]. DNA copy number changes have also shown recurrent small deletions or duplications of the chromosome 16p11.2 band using microarray analysis [25,26] and the chromosome 15q13.2–q13.3 region [27], whereas copy number changes are noted throughout the genome in individuals with ASD, indicating the presence of multiple candidate genes on every human chromosome. These copy number changes are more often of the deletion type.

For idiopathic or non-syndromic autism, the empirical risk for siblings to be similarly affected is between 2% and 8% with an average of 4% [28]. In multiplex families having two or more affected children with autism, the recurrence risk may be as high as 25%, but generally ranges from 13% [29] to 19% [30] if due to single-gene disturbances as the cause, a major focus of this illustrative review. Advances in genetic technology beyond linkage or cytogenetic analysis of affected families with ASD or other complex disorders have led to genome-wide association studies (GWAS) involving hundreds of affected and control individuals by analyzing the distribution and clustering of hundreds and thousands of SNPs that have successfully been searched for candidate genes. The first GWAS for ASD was undertaken by Lauritsen et al. in 2006 [31] using 600 DNA markers in an isolated population of affected individuals from the Faroe Islands. They found an association of the chromosome 3p25.3 band, and later, other investigators studied more subjects with larger collections of genotyped markers and found several chromosome bands and regions ascertained when specific SNPs were over-represented in the ASD subjects, including 5p14.1, 5p15 and 16p13–p21 [32,33,34,35,36,37]. The studies implicated several gene families, including the cadherin family, encoding proteins for neuronal cell adhesion, while other genes (e.g., SEMA5A) were implicated in axonal guidance with lower gene expression levels in brain specimens from individuals with ASD [33], reviewed by Holt and Monaco [17]. Since that time, several additional studies searching for clinically relevant and known genes for ASD have identified a new collection of ASD genes [38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53].

The ability to identify an increased number of SNPs with advanced genetic platforms and extensive approaches using bioinformatics have led to improved access and a more thorough analysis. This has led to comparing genotyping data from GWAS and DNA copy number variants (CNVs) with the identification of structural genetic defects, such as submicroscopic deletions or duplications of the genome, which was not possible a few years ago. Separate studies using array comparative genomic hybridization or microarray analysis to investigate those individuals with ASD continue to yield useful data in identifying candidate genes for ASD in affected individuals [20,21,54]. The yield for microarray analysis is reported to be approximately 20% for identifying deletions or duplications at sites where known or candidate ASD genes are present. The use of more advanced technology, such as next-generation sequencing (whole genome or exome) will yield additional valuable information on the location and description of lesions of genes contributing to ASD with increasing evidence for specific and recurring mutations of single genes involved with neurodevelopment and function, leading to potential therapeutic discoveries and interventions.

Autism is frequent in single-gene conditions, such as fragile X syndrome, tuberous sclerosis, Rett syndrome or neurofibromatosis, but single-gene disorders as a whole account for less than 20% of all cases; therefore, most individuals with ASD are non-syndromic. The heritability of ASD, which takes into consideration the extent of genetic factors contributing to autism, is estimated to be as high as 90% [55]; hence the relevance and continued importance of investigating the role of genetics in the causation of ASD and expanded diagnostic testing to inform and guide treatment for individuals with identifiable genetic disturbances.

A current list of clinically relevant and known candidate genes for ASD is needed for diagnostic testing and genetic counselling purposes in the clinical setting. Historically, a previous list of known or candidate genes showing an association with ASD was reported in 2011 by Holt and Monaco [17] with the placement of 175 genes on chromosome ideograms. A much greater number of validated genes are now recognized as playing a pivotal role in ASD, warranting an updated, revised summary. We will utilize high-resolution chromosome ideograms (850 band level) to plot the location of genes now recognized by searching the literature and website information as playing a documented role in ASD. In tabular form, we will list the individual gene symbol, expanded name or description and chromosome location.

2. Results and Discussion

The diagnostic approach for an individual with ASD should include a clinical genetics evaluation with interviews of parents and health caregivers for the collection and overview of historical problems, a three-generation family pedigree, recording of developmental milestones and description of atypical behaviors along with medical and surgical procedures and a current list of medications and ongoing treatments. Laboratory tests should include lead, thyroid function, lactate and pyruvate levels in order to assess metabolic and mitochondrial functions that may be impacted by an underlying genetic disturbance along with cholesterol and urine collection for organic acid levels. Brain imaging and electroencephalogram patterns should be reviewed, if available. In addition, the ADI-R and ADOS instruments are used to test the diagnosis of ASD.

To further increase the diagnostic yield in individuals with ASD presenting for genetic service, Schaefer et al. [19] proposed and utilized a three-tier approach to include a genetic work-up by a clinical geneticist with expertise in dysmorphology to identify known syndromes with or without dysmorphic features (e.g., birth marks), growth anomalies (e.g., microcephaly, macrocephaly and short stature), viral titers (e.g., rubella) and metabolic screening (urine for organic acids and mucopolysaccharides, plasma lactate and amino acid levels). DNA testing for fragile X syndrome and Rett syndrome in females and males is also available, along with chromosomal and DNA microarrays to examine structural DNA lesions in those with a sporadic form of autism and the use of SNP arrays to examine for regions of homozygosity or uniparental disomy, whereby both members of a chromosome pair come from one parent [56]. Exome sequencing is now available particularly to those affected subjects with a positive family history of autism (multiplex families), if other diagnostic tests are uninformative. PTEN gene mutation screening would be indicated in those patients with extreme macrocephaly (head size > 2 SD) [14], if not previously done, and a review of brain MRI results. Serum and urine uric acid levels and assays for adenylate succinase deficiency should be done to include biochemical genetic studies and mitochondrial genome screening and function [57] if the above testing protocols are not diagnostic. Up to one in five children with ASD show findings of mitochondrial dysfunction [57], and a detailed genetic work-up will significantly increase the yield for the diagnosis of ASD, leading to a better understanding of causation, treatment and more accurate genetic counselling for those presenting for genetic services [20,21,54].

Advances made in genetic technology and bioinformatics have led to vastly improved genetic testing options for application in the clinical setting in patients presenting for genetic services [54]. Significant discoveries have been made with the recognition of genetic defects in the causation of ASD using microarray technology and, now, next generation sequencing. This technology has flourished with a combination of DNA probes used for both copy number variation and SNPs being required to identify segmental deletions and duplications in the genome and regions of homozygosity for the determination of identical by descent for the calculation of inbreeding coefficients or consanguinity status along with uniparental disomy of individual chromosomes [56].

Next generation exome DNA sequencing and RNA sequencing allows for discoveries of disease-causing genes and regulatory sequences required for normal function. Identifying and characterizing molecular signatures for novel or disturbed gene or exon expression and disease-specific profiles and patterns with expression heat maps have led to the recognition of interconnected disturbed gene pathways in many diseases, including a growing body of genetic evidence for autism and other psychiatric or aberrant behavioral disorders [54].

The position for each known or candidate gene for ASD susceptibility is plotted on high-resolution chromosome ideograms (850 band level), as shown in Figure 1 below. We have included gene symbols and expanded names along with the chromosome band location in Table 1 for the 792 genes recognized as playing a role in ASD.

Figure 1.

Figure 1

Figure 1

High-resolution human chromosome ideograms (850 band level) with the ASD gene symbol placed at the chromosomal band location. The centromere area, highlighted in black, separates the upper short “p” arm and lower long “q” arm for each chromosome. The gene symbols are arranged in alphabetical order with the expanded name and chromosome band position listed in Table 1.

Table 1.

Recognized genes for autism spectrum disorders (ASD) and their chromosome locations.

Gene Symbol Gene Name Location
ABAT 4-aminobutyrate aminotransferase 16p13.2
ABCA7 ATP-binding cassette, sub-family A (ABC1), member 7 19p13.3
ABI1 Abl-interactor 1 10p12.1
ABI2 Abl-interactor 2 2q33.2
ABL1 C-Abl oncogene 1, non-receptor tyrosine kinase 9q34.12
ACY1 Aminoacylase 1 3p21.2
ADA Adenosine deaminase 20q13.12
ADAMTS18 A disintegrin-like and metalloproteinase with thrombospondin type 1 motif, 18 16q23.1
ADARB1 Adenosine deaminase, RNA-specific, B1 21q22.3
ADCY5 Adenylate cyclase 5 3q21.1
ADK Adenosine kinase 10q22.2
ADNP Activity-dependent neuroprotector homeobox 20q13.13
ADORA2A Adenosine A2A receptor 22q11.23
ADORA3 Adenosine A3 receptor 1p13.2
ADRB2 Adrenergic, β 2 receptor 5q32
ADSL Adenylosuccinate lyase 22q13.1
AFF2 AF4/fragile X mental retardation 2 (FMR2) family, member 2 Xq28
AFF4 AF4/fragile X mental retardation 2 (FMR2) family, member 4 5q31.1
AGBL4 ATP/GTP binding protein-like 4 1p33
AGMO Alkylglycerol monooxygenase 7p21.1
AGTR2 Angiotensin II receptor, type 2 Xq23
AHI1 Abelson helper integration site 1 6q23.3
AHRR Aryl hydrocarbon receptor repressor 5p15.33
AKT1 v-Akt murine thymoma viral oncogene homolog 1 14q32.33
ALDH1A3 Aldehyde dehydrogenase 1 family, member A3 15q26.3
ALDH5A1 Aldehyde dehydrogenase 5 family, member A1 6p22.3
ALOX5AP Arachidonate 5-lipoxygenase-activating protein 13q12.3
AMPD1 Adenosine monophosphate deaminase 1 1p13.2
AMT Aminomethyltransferase 3p21.31
ANK2 Ankyrin 2 4q25
ANK3 Ankyrin 3 10q21.2
ANKRD11 Ankyrin repeat domain 11 16q24.3
ANXA1 Annexin A1 9q21.13
AP1S2 Adaptor-related protein complex 1, sigma 2 subunit Xp22.2
APBA2 Amyloid β precursor protein-binding, family A, member 2 15q13.1
APC Adenomatosis polyposis coli 5q22.2
APH1A APH1A γ secretase subunit 1q21.2
APOBEC3D Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3D 22q13.1
APP Amyloid β precursor protein 21q21.3
AR Androgen receptor Xq12
ARHGAP11B Rho GTPase activating protein 11B 15q13.2
ARHGAP15 Rho GTPase activating protein 15 2q22.2
ARHGAP24 Rho GTPase activating protein 24 4q22.1
ARHGEF6 RAC/CDC42 guanine nucleotide exchange factor (GEF) 6 Xq26.3
ARID1B AT rich interactive domain 1B (SWI1-like) 6q25.3
ARID5A AT rich interactive domain 5A (MRF1-like) 2q11.2
ARL6IP6 ADP-ribosylation-like factor 6 interacting protein 6 2q23.3
ARNT2 Aryl-hydrocarbon receptor nuclear translocator 2 15q25.1
ARX Aristaless related homeobox Xp21.3
ASH1L Ash1 (absent, small, or homeotic)-like (Drosophila) 1q22
ASMT Acetylserotonin O-methyltransferase, X-chromosomal Xp22.33
ASMT Acetylserotonin O-methyltransferase, Y-chromosomal Yp11.32
ASPHD1 Aspartate β-hydroxylase domain containing 1 16p11.2
ASPM Asp (abnormal spindle) homolog, microcephaly associated 1q31.3
ASS1 Argininosuccinate synthetase 9q34.1
ASTN2 Astrotactin 2 9q33.1
ASXL3 Additional sex combs-like 3 18q12.1
ATG7 Autophagy related 7 3p25.3
ATP10A ATPase, Class V, type 10A 15q11.2
ATP2B2 ATPase, Ca++ transporting, plasma membrane 2 3p25.3
ATRNL1 Attractin-like 1 10q25.3
ATRX α thalassemia/mental retardation syndrome X-linked Xq21.1
ATXN7 Ataxin 7 3p14.1
AUTS2 Autism susceptibility candidate 2 7q11.22
AVPR1A Arginine vasopressin receptor 1A 12q14.2
AXL AXL receptor tyrosine kinase 19q13.2
BAIAP2 BAI1-associated protein 2 17q25.3
BBS4 Bardet-Biedl syndrome 4 15q24.1
BCKDK Branched chain ketoacid dehydrogenase kinase 16p11.2
BCL11A B-Cell CLL/lymphoma 11A (zinc finger protein) 2p16.1
BCL2 B-cell CLL/lymphoma 2 18q21.33
BCORL1 Bc16 co-repressor-like 1 Xq26.1
BDNF Brain-derived neurotrophic factor 11p14.1
BIN1 Bridging integrator 1 2q14.3
BIRC6 Baculoviral IAP repeat containing 6 2p22.3
BRAF v-Raf murine sarcoma viral oncogene homolog B 7q34
BRCA2 Breast cancer 2, early onset 13q13.1
BTAF1 RNA polymerase II, B-TFIID transcription factor-associated, 170 kDa (Mot1 homolog, S. cerevisiae) 10q23.32
BZRAP1 Benzodiazepine receptor (peripheral) associated protein 1 17q23.2
C11ORF30 Chromosome 11 open reading frame 30 11q13.5
C12ORF57 Chromosome 12 open reading frame 57 12p13.31
C15ORF43 Chromosome 15 open reading frame 43 15q21.1
C3ORF58 Chromosome 3 open reading frame 58 3q24
C4B Complement component 4B 6p21.33
CA6 Carbonic anhydrase VI 1p36.2
CACNA1B Calcium channel, voltage-dependent, N type, α 1B subunit 9q34.3
CACNA1C Calcium channel, voltage-dependent, L type, α 1C subunit 12p13.33
CACNA1D Calcium channel, voltage-dependent, L type, α 1D subunit 3p14.3
CACNA1F Calcium channel, voltage-dependent, α 1F subunit Xp11.23
CACNA1G Calcium channel, voltage-dependent, T type, α 1G subunit 17q21.33
CACNA1H Calcium channel, voltage-dependent, α 1H subunit 16p13.3
CACNA1I Calcium channel, voltage-dependent, T type, α 1I subunit 22q13.1
CACNA2D3 Calcium channel, voltage-dependent, α 2/δ subunit 3 3p21.1
CACNB2 Calcium channel, voltage-dependent, β 2 subunit 10p12.33
CADM1 Cell adhesion molecule 1 11q23.3
CADPS2 Ca++-dependent activator protein for secretion 2 7q31.32
CALM1 Calmodulin 1 (phosphorylase kinase, δ) 14q32.11
CAMK4 Calcium/calmodulin-dependent protein kinase 5q22.1
CAMSAP2 Calmodulin regulated spectrin-associated protein family, member 2 1q32.1
CAMTA1 Calmodulin binding transcription activator 1 1p36.31
CAPRIN1 Cell cycle associated protein 1 11p13
CASC4 Cancer susceptibility candidate 4 15q15.3
CBS Cystathionine β-synthase 21q22.3
CCAR2 Cell cycle and apoptosis regulator 2 8p21.3
CC2D1A Coiled-coil and C2 domain-containing 1A 19p13.12
CCDC19 Coiled-coil domain-containing protein 19 1q23.2
CCDC64 Coiled-coil domain-containing 64 12q24.23
CD38 CD38 molecule 4p15.32
CD44 CD44 molecule 11p13
CD163L1 CD163 molecule-like 1 12p13.31
CD99L2 CD99 molecule-like 2 Xq28
CDC42BPB CDC42 binding protein kinase β (DMPK-like) 14q32.32
CDH10 Cadherin 10, type 2 5p14.2
CDH22 Cadherin-like 22 20q13.1
CDH8 Cadherin 8, type 2 16q22.1
CDH9 Cadherin 9, type 2 5p14.1
CDH11 Cadherin 11, type 2 16q21
CDKL5 Cyclin-dependent kinase-like 5 Xp22.13
CDKN1B Cyclin-dependent kinase inhibitor 1B 12p13.1
CECR2 Cat eye syndrome chromosome region, candidate 2 22q11.21
CELF4 CUGBP, Elav-like family, member 4 18q12.2
CELF6 CUGBP, Elav-like family, member 6 15q23
CENTG2 Centaurin γ-2 2q37.2
CEP170R Centrosomal protein 170B 14q32.33
CEP290 Centrosomal protein 290 kDa 12q21.32
CEP41 Centrosomal protein 41 kDa 7q32.2
CHD1 Chromodomain helicase DNA binding protein 1 5q21.1
CHD2 Chromodomain helicase DNA binding protein 2 15q26.1
CHD3 Chromodomain helicase DNA binding protein 3 17p13.1
CHD7 Chromodomain helicase DNA binding protein 7 8q12.2
CHD8 Chromodomain helicase DNA binding protein 8 14q11.2
CHRM3 Cholinergic receptor, muscarinic 3 1q43
CHRNA7 Cholinergic receptor, neuronal nicotinic, α 7 15q13.3
CHRNB3 Cholinergic receptor, neuronal nicotinic, β 3 8p11.21
CHST5 Carbohydrate sulfotransferase 5 16q22.3
CIB2 Calcium and integrin binding family member 2 15q25.1
CKAP5 Cytoskeleton associated protein 5 11p11.2
CLCNKB Chloride channel voltage-sensitive kidney, B 1p36.13
CLSTN3 Calsyntenin 3 12p13.31
CLTCL1 Clathrin, heavy chain-like 1 22q11.21
CMIP c-MAF inducing protein 16q23.2
CNR1 Cannabinoid receptor 1 6q15
CNR2 Cannabinoid receptor 2 1p36.11
CNTN3 Contactin 3 3p12.3
CNTN4 Contactin 4 3p26.3
CNTN5 Contactin 5 11q22.1
CNTN6 Contactin 6 3p26.3
CNTNAP2 Contactin associated protein-like 2 7q35
CNTNAP3 Contactin associated protein-like 3 9p13.1
CNTNAP4 Contactin associated protein-like 4 16q23.1
CNTNAP5 Contactin associated protein-like 5 2q14.3
COL7A1 Collagen, type VII, α 1 3p21.31
COPS2 Thyroid hormone receptor interactor 15 15q21.1
CREBBP CREB binding protein 16p13.3
CSMD1 Cytoskeleton associated protein 5 11p11.2
CSNK1D Casein kinase 1, δ 17q25
CSTF2T Cleavage stimulation factor, 3' pre-RNA, subunit 2, 64 kDa, tau 10q21.1
CTCF CCCTC-binding factor 16q22.1
CTNNA3 Catenin (cadherin-associated protein), α 3 10q21.3
CTNNB1 Catenin (cadherin-associated protein), β 1, 88 kDa 3p22.1
CTSB Cathepsin B 8p23.1
CTTNBP2 Cortactin binding protein 2 7q31.31
CTU2 Cytosolic thiouridylase subunit 2 homolog (S. pombe) 16q24.3
CUEDC2 CUE domain containing 2 10q24.32
CUL5 Cullin 5 11q22.3
CUL3 Cullin 3 2q36.2
CX3CR1 Chemokine (C-X3-C motif) receptor 1 3p22.2
CXCR3 Chemokine, CXC motif, receptor 3 Xq13.1
CYFIP1 Cytoplasmic FMRP interacting protein 1 15q11.2
CYP11B1 Cytochrome P450, subfamily XIB, polypeptide 1 8q24.3
DAB1 Disabled homolog 1 1p32.2
DAG1 Dystroglycan 1 (dystrophin-associated glycoprotein 1) 3p21.31
DAGLA Diacylglycerol lipase, α 11q12.2
DAPK1 Death-associated protein kinase 1 9q21.33
DAPP1 Dual adaptor of phosphotyrosine and 3-phosphoinositides 1 4q23
DCAF13 DDB1 and CUL4 associated factor 13 8q22.3
DCAKD Dephospho-CoA kinase domain-containing protein 17q21.31
DCTN5 Dynactin 5 16p12.2
DCUN1D1 DCN1, domain containing protein 1 3q27.1
DCX Doublecortin Xq23
DDC DOPA decarboxylase 7p12.1
DDX11 DEAD (Asp-Glu-Ala-Asp)/H box 11 12p11.21
DDX53 DEAD (Asp-Glu-Ala-Asp) box polypeptide 53 Xp22.11
DEAF1 DEAF1 transcription factor 11p15.5
DEPDC5 DEP domain containing 3 protein 5 22q12.2
DHCR7 7-dehydrocholesterol reductase 11q13.4
DHX9 DEAH (Asp-Glu-Ala-His) box helicase 9 1q25.3
DIAPH3 Diaphanous, Drosophila, homolog 3 13q21.2
DIP2A DIP2 disco-interacting protein 2 homolog A (Drosophila) 21q22.3
DISC1 Disrupted in schizophrenia 1 1q42.2
DLG4 Discs, large, Drosophila, homolog 4 17p13.1
DLGAP2 Discs, large- associated protein 2 8p23.3
DLGAP3 Discs, large- associated protein 3 1p34.3
DLL1 δ-like 1 (Drosophila) 6q27
DLX1 Distal-less homeobox 1 2q31.1
DLX2 Distal-less homeobox 2 2q31.1
DLX6 Distal-less homeobox 6 7q21.3
DMD Dystrophin Xp21.1
DMPK Dystrophia myotonica-protein kinase 19q13.32
DNAJC19 DNAJ Hsp40 homolog, subfamily C, member 19 3q26.33
DNER δ- and notch-like epidermal growth factor-related receptor 2q36.3
DNM1L Dynamin 1-like 12p11.21
DNMT3A DNA (cytosine-5)-methyltransferase 3 α 2p23.3
DOCK4 Dedicator of cytokinesis 4 7q31.1
DOCK10 Dedicator of cytokinesis 10 2q36.2
DOLK Dolichol kinase 9q34.1
DPP10 Dipeptidyl peptidase 10 2q14.1
DPP6 Dipeptidyl peptidase 6 7q36.2
DPYD Dihydropyrimidine dehydrogenase 1p21.3
DRD1 Dopamine receptor D1 5q35.2
DRD2 Dopamine receptor D2 11q23.2
DRD3 Dopamine receptor D3 3q13.31
DSCAM Down syndrome cell adhesion molecule 21q22.2
DST Dystonin 6p12.1
DUSP22 Dual specificity phosphatase 22 6p25.3
DYDC1 DPY30 domain containing 1 10q23.1
DYDC2 DPY30 domain containing 2 10q23.1
DYRK1A Dual-specificity tyrosine-phosphorylation-regulated kinase 1A 21q22.13
EEF1A2 Eukaryotic translation elongation factor 1 α 2 20q13.33
EFR3A EFR3 homolog A (S. cerevisiae) 8q24.22
EGR2 Early growth response 2 10q21.3
EHMT1 Euchromatic histone methyltransferase 1 9q34.3
EIF2S3 Eukaryotic translation initiation factor 2, subunit 3 γ Xp22.11
EIF4E Eukaryotic translation initiation factor 4E 4q23
EIF4EBP2 Eukaryotic translation initiation factor 4E binding protein 2 10q22.1
EML1 Echinoderm microtubule associated protein like 1 14q32.2
EN2 Engrailed 2 7q36.3
EP300 E1A binding protein p300 22q13.2
EP400 E1A binding protein p400 12q24.33
EPC2 Enhancer of polycomb, Drosophila homolog of 2 2q23.1
EPHA6 Ephrin receptor A6 3q11.2
EPHB2 Ephrin receptor B2 1p36.12
EPHB6 Ephrin receptor B6 7q34
EPS8 Epidermal growth factor receptor pathway substrate 8 12p12.3
ERBB4 v-ERB-A avian erythroblastic leukemia viral oncogene homolog 4 2q34
ERG v-ETS avian erythroblastosis virus E26 oncogene homolog 21q22.2
ESR1 Estrogen receptor 1 6q25.1
ESR2 Estrogen receptor 2 14q23.2
ESRRB Estrogen-related receptor β 14q24.3
ETFB Electron-transfer-flavoprotein, β polypeptide 19q13.41
ETV1 Ets variant 1 7p21.2
EXOC6B Exocyst complex component 6B 2p13.2
EXT1 Exostosin 1 8q24.11
F13A1 Factor XIII, A1 subunit 6p25.1
FABP3 Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor) 1p35.2
FABP5 Fatty acid binding protein 5 8q21.13
FABP7 Fatty acid binding protein 7 6q22.31
FAM135B Family with sequence similarity 135, member B 8q24.23
FAN1 FANCD2/FANCI-associated nuclease 1 15q13.2
FAT1 FAT tumor suppressor, Drosophila homolog of, 1 4q35.2
FAT3 FAT tumor suppressor, Drosophila homolog of , 3 11q14.3
FBXO15 F-box protein 15 18q22.3
FBXO33 F-box protein 33 14q21.1
FBXO40 F-box protein 40 3q13.33
FBXW7 F-box and WD repeat domain containing 7, E3 ubiquitin protein 4q31.3
FER FPS/FES related tyrosine kinase 5q21.3
FEZF2 FEZ family zinc finger 2 3p14.2
FGA Fibrinogen, A α polypeptide 4q31.3
FGD1 FYVE, Rho GEF and PH domain containing 1 Xp11.22
FGFBP3 Fibroblast growth factor binding protein 3 10q23.32
FHIT Fragile histidine triad 3p14.2
FLT1 c-FMS-related tyrosine kinase 1 13q12.3
FMR1 Fragile X mental retardation 1 (FMR1) Xq27.3
FOLH1 Folate hydrolase 1 11p11.2
FOXG1 Forkhead box G1 14q12
FOXP1 Forkhead box P1 3p13
FOXP2 Forkhead box P2 7q31.1
FRK FYN-related kinase 6q22.1
FRMPD4 FERM and PDZ domain containing protein 4 Xp22.2
GABRA1 γ-aminobutyric acid A receptor, α 1 5q34
GABRA3 γ-aminobutyric acid receptor, α 3 Xq28
GABRA4 γ-aminobutyric acid receptor, α 4 4p12
GABRB1 γ-aminobutyric acid receptor, β 1 4p12
GABRB3 γ-aminobutyric acid receptor, β 3 15q12
GABRQ γ-aminobutyric acid receptor, θ Xq28
GAD1 Glutamate decarboxylase 1 (brain, 67 kDa) 2q31.1
GALNT13 UDP-N-acetyl-α-d-galactosamine:polypeptide N-acetylgalactosaminyl-transferase 13 2q23.3
GALNT14 UDP-N-acetyl-α-d-galactosamine:polypeptide N-acetylgalactosaminyl-transferase 14 2p23.1
GAN Gigaxonin 16q24.1
GAP43 Growth associated protein 43 3q13.31
GAS2 Growth arrest-specific 2 11p14.3
GATM Glycine amidinotransferase (l-arginine:glycine amidinotransferase) 15q21.1
GDI1 GDP dissociation inhibitor 1 Xq28
GIGYF1 GRB10 interacting GYF protein 1 7q22.1
GLO1 Glyoxalase I 6p21.2
GLRA2 Glycine receptor, α 2 subunit Xp22.2
GNA14 Guanine nucleotide-binding protein, α 14 9q21.2
GNAS Guanine nucleotide-binding protein, α-stimulating activity polypeptide I complex locus 20q13.32
GNB1L Guanine nucleotide-binding protein, β 1-like 22q11.21
GPC6 Glypican 6 13q31.3
GPD2 Glycerol-3-phosphate dehydrogenase 2 2q24.1
GPHN Gephyrin 14q23.3
GPR139 G protein-coupled receptor 139 16p12.3
GPR37 G protein-coupled receptor 37 7q31.33
GPRASP2 G protein-coupled receptor associated sorting protein 2 Xq22.1
GPX1 Glutathione peroxidase 1 3p21.31
GRID1 Glutamate receptor, ionotropic, δ 1 10q23.2
GRID2 Glutamate receptor, ionotropic, δ 2 4q22.1
GRIK2 Glutamate receptor, ionotropic, kainate 2 6q16.3
GRIN1 Glutamate receptor, ionotropic, N-methyl d-aspartate 1 9q34.3
GRIN2A Glutamate receptor, ionotropic, N-methyl d-aspartate 2A 16p13.2
GRIN2B Glutamate receptor, ionotropic, N-methyl d-aspartate 2B 12p13.1
GRINL1A GRINL1A complex locus 1 15q21.3
GRIP1 Glutamate receptor interacting protein 1 12q14.3
GRM1 Glutamate receptor, metabotropic 1 6q24.3
GRM4 Glutamate receptor, metabotropic 4 6p21.31
GRM5 Glutamate receptor, metabotropic 5 11q14.3
GRM8 Glutamate receptor, metabotropic 8 7q31.33
GRPR Gastrin-releasing peptide receptor Xp22.2
GSE1 Gse1 coiled-coil protein 16q24.1
GSK3B Glycogen synthase kinase 3 β 3q13.33
GSN Gelsolin 9q33.2
GSTM1 Glutathione S-transferase M1 1p13.3
GTF2I General transcription factor III 7q11.23
GTF2IRD1 GTF2I repeat domain containing 1 7q11.23
GTF3C1 General transcription factor IIIC, polypeptide 1, α 16p12.1
GUCY1A2 Guanylate cyclase 1, soluble, α 2 11q22.3
HCAR1 Hydroxycarboxylic acid receptor 1/G protein-coupled receptor 81 12q24.31
HCFC1 Host cell factor C1 Xq28
HCN1 Hyperpolarization activated cyclic nucleotide-gated potassium channel 1 5p12
HDAC4 Histone deacetylase 4 2q37.3
HDAC6 Histone deacetylase 6 Xp11.23
HDAC9 Histone deacetylase 9 7p21.1
HDLBP High density lipoprotein binding protein 2q37.3
HEPACAM Hepatic and glial cell adhesion molecule 11q24.2
HERC2 HECT domain and RCC1-like domain 2 15q13.1
HLA-A Major histocompatibility complex, class I, A 6p22.1
HLA-DRB1 Major histocompatibility complex, class II, DR β 1 6p21.32
HMGN1 High mobility group nucleosome binding domain 1 21q22.2
HNRNPF Heterogeneous nuclear ribonucleoprotein F 10q11.21
HNRNPH2 Heterogeneous nuclear ribonucleoprotein H2 Xq22.1
HNRNPUL1 Heterogeneous nuclear ribonucleoprotein U-like 1 19q13.2
HOMER1 Homer, Drosophila, homolog 1 of 1 5q14.1
HOXA1 Homeobox A1 7p15.3
HOXB1 Homeobox B1 17q21.32
HRAS v-HA-RAS Harvey rat sarcoma viral oncogene homolog 11p15.5
HS3ST5 Heparan sulfate 3-O-sulfotransferase 5 6q22.31
HSD11B1 11-β-hydroxysteroid dehydrogenase type 1 1q32.2
HSPA4 Heat shock 70 kDa protein 4 5q31.1
HTR1B 5-hydroxytryptamine receptor 1B 6q14.1
HTR2A 5-hydroxytryptamine receptor 2A 13q14.2
HTR3A 5-hydroxytryptamine receptor 3A 11q23.2
HTR3C 5-hydroxytryptamine receptor 3, family member C 3q27.1
HTR7 5-hydroxytryptamine receptor 7 10q23.31
HUWE1 HECT, UBA and WWE domain containing 1, E3 ubiquitin protein ligase Xp11.22
HYDIN Hydrocephalus-inducing, mouse, homolog of 16q22.2
ICA1 Islet cell autoantigen 1 7p21.3
IL1R2 Interleukin 1 receptor, type II 2q11.2
IL1RAPL1 Interleukin 1 receptor accessory protein-like 1 Xp21.3
IL1RAPL2 Interleukin 1 receptor accessory protein-like 2 Xq22.3
IMMP2L Inner mitochondrial membrane peptidase, subunit 2, S. cerevisiae, homolog of 7q31.1
IMPDH2 Inosine-5-prime monophosphate dehydrogenase 2 3p21.31
INADL Inactivation no after-potential D-like 1p31.3
INPP1 Inositol polyphosphate-1-phosphatase 2q32.2
INPP5 Inositol polyphosphate-5-phosphatase 17p13.3
IQSEC2 IQ motif and Sec7 domain 2 Xp11.22
ITGA4 Integrin, α 4 2q31.3
ITGB3 Integrin, β 3 17q21.32
ITGB7 Integrin, β 7 12q13.13
ITK IL20 inducible t-cell kinase 5q33.3
JARID2 Jumonji, AT rich interactive domain 2 6p22.3
JMJD1C Jumonji domain containing 1C 10q21.3
JUP Junction plakoglobin 17q21.2
KAL1 Kallmann syndrome interval 1 Xp22.31
KANK1 KN motif and ankyrin repeat domains 1 9p24.3
KATNAL2 Katanin p60 subunit A-like 2 18q21.1
KCND2 Potassium voltage-gated channel, Shal-related subfamily, member 2 7q31.31
KCNJ2 Potassium inwardly-rectifying channel, subfamily J, member 2 17q24.3
KCNJ10 Potassium inwardly-rectifying channel, subfamily J, member 10 1q23.2
KCNMA1 Potassium large conductance calcium-activated channel, subfamily M, α member 1 10q22.3
KCNQ2 Potassium voltage-gated channel, KQT-like subfamily, member 2 20q13.3
KCNQ3 Potassium voltage-gated channel, KQT-like subfamily, member 3 8q24.22
KCNT1 Potassium channel, subfamily T, member 1 9q34.3
KCTD13 Potassium channel tetramerization domain containing protein 13 16p11.2
KDM5A Lysine (K)-specific demethylase 5A 12p13.33
KDM5B Lysine (K)-specific demethylase 5B 1q32.1
KDM5C Lysine (K)-specific demethylase 5C Xp11.22
KDM6B Lysine (K)-specific demethylase 6B 17p13.1
KHDRBS2 KH domain containing, RNA binding, signal transduction associated protein 2 6q11.1
KIAA1217 Sickle tail protein homolog 10p12.31
KIAA1586 KIAA1586 6p12.1
KIAA2022 KIAA2022 Xq13.3
KIF5C Kinesin family member 5C 2q23.1
KIRREL3 Kin of IRRE like 3 11q24.2
KIT v-KIT Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog 4q12
KLC2 Kinesin light chain 2 11q13.2
KMO Kynurenine 3-monooxygenase 1q43
KMT2A Lysine (K)-specific methyltransferase 2A 11q23.3
KMT2C Lysine (K)-specific methyltransferase 2C 7q36.1
KMT2E Lysine (K)-specific methyltransferase 2E 7q22.3
KPTN Kaptin (actin binding protein) 19q13.32
LAMA1 Laminin, α 1 18p11.23
LAMB1 Laminin, β 1 7q31.1
LAMC3 Laminin, γ 3 9q34.1
LEP Leptin 7q32.1
LIN7B Lin-7 homolog B (C. elegans) 19q13.33
LMNA Lamin A/C 1q22
LMX1B LIM homeobox transcription factor 1, β 9q33.3
LRFN5 Leucine-rich repeats and fibronectin type III domain containing 5 14q21.1
LRGUK Leucine-rich repeats and guanylate kinase domain containing 7q33
LRP2 Low density lipoprotein receptor-related protein 2 2q31.1
LRPPRC Leucine-rich PPR motif containing protein 2p21
LRRC1 Leucine-rich repeat-containing protein 1 6p12.1
LRRC4 Leucine-rich repeat-containing protein 4 7q32.1
LRRC7 Leucine-rich repeat-containing protein 7 1p31.1
LZTS2 Leucine zipper, putative tumor suppressor 2 10q24.31
MACROD2 Macro domain containing 2 20p12.1
MAGED1 Melanoma antigen family D, 1 Xp11.22
MAGEL2 MAGE-like 2 15q11.2
MAOA Monoamine oxidase A Xp11.3
MAOB Monoamine oxidase B Xp11.23
MAP1A Microtubule-associated protein 1A 15q15.3
MAP2 Microtubule-associated protein (MAP) 2 2q34
MAP4 Microtubule-associated protein (MAP) 4 3p21.31
MAPK1 Mitogen-activated protein kinase 1 22q11.22
MAPK3 Mitogen-activated protein kinase 3 16p11.2
MAPK8IP2 Mitogen-activated protein kinase 8 interacting protein 2 22q13.33
MARK1 MAP/microtubule affinity-regulating kinase 1 1q41
MBD1 Methyl-CpG binding domain protein 1 18q21.1
MBD3 Methyl-CpG binding domain protein 3 19p13.3
MBD4 Methyl-CpG binding domain protein 4 3q21.3
MBD5 Methyl-CpG binding domain protein 5 2q23.1
MBD6 Methyl-CpG binding domain protein 6 12q13.2
MC4R Melanocortin 4 receptor 18q21.32
MCC Mutated in colorectal cancers 5q22.2
MCPH1 Microcephalin 1 8p23.1
MDGA2 Mephrin, A5 antigen, protein tyrosine phosphatase mu (MAM) domain containing glycosylphosphatidylinositol anchor 2 14q21.3
MDM2 MDM2 oncogene, E3 ubiquitin protein ligase 12q15
MECP2 Methyl CpG binding protein 2 Xq28
MED12 Mediator complex subunit 12 Xq13.1
MED13L Mediator complex subunit 13-like 12q24.21
MEF2C MADS box transcription myocyte enhancer factor 2, polypeptide C 5q14.3
MET Met proto-oncogene 7q31.2
MIB1 Mind bomb E3 ubiquitin protein ligase 1 18q11.2
MICAL3 Microtubule-associated monooxygenase, calponin and lim domains-containing, 3 22q11.21
MICALCL MICAL C-terminus-like protein 11p15.3
MKL2 Myocardin-like 2 16p13.12
MOV10 Moloney leukemia virus 10, mouse, homolog of 1p13.2
MSN Moesin Xq12
MSNP1AS Moesin pseudogene 1 antisense 5p14.1
MSR1 Macrophage scavenger receptor 8p22
MTF1 Metal-regulatory transcription factor 1 1p34.3
MTHFR 5-10-methylene-tetrahydrofolate reductase 1p36.22
MTR 5-methyltetrahydrofolate-homocysteine S-methyltransferase 1q43
MTX2 Metaxin 2 2q31.1
MXRA5 Matrix-remodelling associated 5 Xp22.2
MYH4 Myosin, heavy chain 4, skeletal muscle 17p13.1
MYH10 Myosin, heavy chain 10, non-muscle 17p13.1
MYO16 Myosin XVI 13q33.3
MYO1A Myosin IA 12q13.3
MYO9B Myosin IXB 19p13.11
MYT1L Myelin transcription factor 1-like 2p25.3
NAA15 N(α)-acetyltransferase 15, NatA auxiliary subunit 4q31.1
NASP Nuclear autoantigenic sperm protein (histone-binding) 1p34.1
NAV1 Neuron navigator 1 1q32.1
NBEA Neurobeachin 13q13.3
NCKAP1 NCK-associated protein 1 2q32.1
NCKAP5 NCK-associated protein 5 2q21.2
NCKAP5L NCK-associated protein 5-like 12q13.12
NCOR1 Nuclear receptor corepressor 1 17p11.2
NDNL2 Necdin-like gene 2 15q13.1
NDUFA5 NADH-ubiquinone oxidoreductase 1 α subcomplex, 5 7q31.32
NEFL Neurofilament protein, light polypeptide 8p21.2
NELL1 NEL-like 1 11p15.1
NF1 Neurofibromin 1 17q11.2
NFIA Nuclear factor I/A 1p31.3
NIPA1 Non imprinted gene in Prader-Willi/Angelman syndrome chromosomal region 1 15q11.2
NIPA2 Non imprinted gene in Prader-Willi/Angelman syndrome chromosomal region 2 15q11.2
NIPBL Nipped-B-like 5p13.2
NLGN1 Neuroligin 1 3q26.31
NLGN2 Neuroligin 2 17p13.1
NLGN3 Neuroligin 3 Xq13.1
NLGN4X Neuroligin 4, X-linked Xp22.31
NLGN4Y Neuroligin 4, Y-linked Yq11.221
NOS1AP Nitric oxide synthase 1 (neuronal) adaptor protein 1q23.3
NOS2A Nitric oxide synthase 2A 17q11.2
NOTCH3 Notch 3 19p13.12
NPAS2 Neuronal PAS domain protein 2 2q11.2
NR0B1 Nuclear receptor subfamily 0, group B, member 1 Xp21.2
NR3C2 Nuclear receptor subfamily 3, group C, member 2 4q31.23
NR4A1 Nuclear receptor subfamily 4, group A, member 1 12q13.13
NRCAM Neuronal cell adhesion molecule 7q31.1
NRG1 Neuregulin 1 8p12
NRP2 Neuropilin 2 2q33.3
NRXN1 Neurexin I 2p16.3
NRXN2 Neurexin II 11q13.1
NRXN3 Neurexin III 14q24.3
NSD1 Nuclear receptor-binding Sa-var, enhancer of zeste, and trithorax domain protein 1 5q35.3
NTNG1 Netrin G1 1p13.3
NTRK1 Neurotrophic tyrosine kinase, receptor, type 1 1q23.1
NTRK3 Neurotrophic tyrosine kinase, receptor, type 3 15q25.3
NXF5 Nuclear RNA export factor 5 Xq22.1
NXPH1 Neurexophilin 1 7p21.3
ODF3L2 Outer dense fiber of sperm tails 3-like 2 19p13.3
OGT O-linked N-acetylglucosamine transferase Xq13.1
OPHN1 Oligophrenin 1 Xq12
OPRM1 Opioid receptor, mu 1 6q25.2
OR1C1 Olfactory receptor, family 1, subfamily C, member 1 1q44
OTX1 Orthodenticle Drosophila, homolog of 2p15
OXTR Oxytocin receptor 3p25.3
P2RX4 Purinergic receptor P2X, ligand-gated ion channel, 4 12q24.31
PAFAH1B1 Platelet-activating factor acetylhydrolase 1B, regulatory subunit 1 17p13.3
PAH Phenylalanine hydroxylase 12q23.2
PARD3B PAR-3 family cell polarity regulator β 2q33.3
PARK2 Parkin 6q26
PAX5 Paired box 5 9p13.2
PBRM1 Polybromo 1 3p21.1
PCDH10 Protocadherin 10 4q28.3
PCDH15 Protocadherin 15 10q21.1
PCDH19 Protocadherin 19 Xq22.1
PCDH8 Protocadherin 8 13q14.3
PCDH9 Protocadherin 9 13q21.32
PCDHA1 Protocadherin α 1 5q31.3
PCDHA10 Protocadherin α 10 5q31.3
PCDHA11 Protocadherin α 11 5q31.3
PCDHA12 Protocadherin α 12 5q31.3
PCDHA13 Protocadherin α 13 5q31.3
PCDHA2 Protocadherin α 2 5q31.3
PCDHA3 Protocadherin α 3 5q31.3
PCDHA4 Protocadherin α 4 5q31.3
PCDHA5 Protocadherin α 5 5q31.3
PCDHA6 Protocadherin α 6 5q31.3
PCDHA7 Protocadherin α 7 5q31.3
PCDHA8 Protocadherin α 8 5q31.3
PCDHA9 Protocadherin α 9 5q31.3
PCDHAC1 Protocadherin α subfamily C, member 1 5q31.3
PCDHAC2 Protocadherin α subfamily C, member 2 5q31.3
PCDHGA11 Protocadherin γ subfamily A, member 11 5q31.3
PDE1C Phosphodiesterase 1C 7p14.3
PDE4A Phosphodiesterase 4A, cAMP-specific 19p13.2
PDE4B Phosphodiesterase 4B, cAMP-specific 1p31.3
PDZD4 PDZ domain containing 4 Xq28
PECR Peroxisomal trans-2-enoyl-CoA reductase 2q35
PER1 Period, Drosophila, homolog of 17p13.1
PEX7 Peroxisomal biogenesis factor 7 6q23.3
PGD Phosphogluconate dehydrogenase 1p36.22
PHF2 PHD finger protein 2 9q22.31
PHF8 PHD finger protein 8 Xp11.22
PIAS1 Protein inhibitor of activated STAT, 1 15q23
PIK3CG Phosphatidylinositol-3-kinase, catalytic, γ 7q22.3
PIK3R2 Phosphatidylinositol-3-kinase, regulatory subunit 2 19q13.11
PINX1 PIN2 interacting protein 1 8p23.1
PITX1 Paired-like homeodomain transcription factor 1 5q31.1
PLAUR Plasminogen activator receptor, urokinase-type 19q13.31
PLCB1 Phospholipase C, β 1 20p12.3
PLCD1 Phospholipase C, δ 1 3p22.2
PLN Phospholamban 6q22.31
PLXNA4 Plexin A4 7q32.3
POGZ POGO transposable element with ZNF domain 1q21.3
POLR2L Polymerase (RNA) II (DNA directed) polypeptide L, 7.6 kDa 11p15.5
POMGNT1 Protein O-mannose β-1, 2-N-acetylglucosaminyl-transferase 1p34.1
PON1 Paraoxonase 1 7q21.3
POT1 Protection of telomeres 1 7q31.33
PPFIA1 Protein tyrosine phosphatase, receptor type, F polypeptide, interacting protein, α 1 11q13.3
PPP1CB Protein phosphatase 1, catalytic subunit, β isozyme 2p23.2
PPP1R1B Protein phosphatase 1, regulatory (inhibitor) subunit 1B 17q12
PPP1R3F Protein phosphatase 1, regulatory (inhibitor) subunit 3F Xp11.23
PRODH Proline dehydrogenase (oxidase) 1 22q11.21
PRICKLE1 Prickle, Drosophila, homolog of, 1 12q12
PRICKLE2 Prickle, Drosophila, homolog of, 2 3p14.1
PRKCB Protein kinase C, β 16p12.2
PRKCB1 Protein kinase C, β-1 16p12.2
PRKD1 Protein kinase D1 14q12
PRDX1 Peroxiredoxin 1 1p34.1
PRSS38 Protease, serine, 38 1q42.13
PRUNE2 Prune, Drosophila, homolog of, 2 9q21.2
PSD3 Pleckstrin and Sec7 domains-containing protein 3 8p22
PSEN1 Presenilin 1 14q24.2
PSMD10 Proteasome 26S subunit, non-ATPase, 10 Xq22.3
PTCHD1 Patched domain containing protein 1 Xp22.11
PTEN Phosphatase and tensin homolog 10q23.31
PTGER3 Prostaglandin E receptor 3, EP3 subtype 1p31.1
PTGS2 Prostaglandin-endoperoxide synthase 2 1q31.1
PTPN11 Protein tyrosine phosphatase, non-receptor type 11 12q24.13
PTPRB Protein tyrosine phosphatase, receptor type, B 12q15
PTPRC Protein tyrosine phosphatase, receptor type, C 1q31.3
PTPRM Protein tyrosine phosphatase, receptor type, M 18p11.23
PTPRT Protein tyrosine phosphatase, receptor type, T 20q13.11
PXDN Peroxidasin, Drosophila homolog of 2p25.3
RAB11FIP5 RAB11 family-interacting protein 5 2p13.2
RAB19 RAB19, member RAS oncogene family 7q34
RAB39B RAS-associated protein RAB39B Xq28
RAI1 Retinoic acid induced gene 1 17p11.2
RAPGEF4 Rap guanine nucleotide exchange factor 2q31.1
RASD1 RAS protein, dexamethasone-induced, 1 17p11.2
RASSF1 RAS association (ralGDS/AF-6) domain family member 1 3p21.31
RASSF5 RAS association domain family protein 5 1q32.1
RB1CC1 RB1-inducible coiled-coil 1 8q11.23
RBFOX1 RNA binding protein FOX-1, C. elegans, homolog of, 1 16p13.3
RBM8A RNA binding motif protein 8A 1q21.1
RBMS3 RNA binding motif protein, single stranded interacting, 3 3p24.1
REEP3 Receptor expression-enhancing protein 3 10q21.3
RELN Reelin 7q22.1
RERE RE-repeats encoding gene 1p36.23
RFWD2 Ring finger and WD repeat domains-containing protein 2 1q25.2
RGS7 Regulator of G protein signaling 7 1q43
RHOXF1 RHOX homeobox family, member 1 Xq24
RIC8A RIC8 guanine nucleotide exchange factor A 11p15.5
RIMS1 Regulating synaptic membrane exocytosis 1 6q13
RIMS3 Protein regulating synaptic membrane exocytosis 3 1p34.2
RNPS1 RNA binding protein S1 16p13.3
ROBO1 Roundabout, Drosophila, homolog of, 1 3p12.2
ROBO2 Roundabout, Drosophila, homolog of, 2 3p12.3
RORA RAR-related orphan receptor A 15q22.2
RPL10 Ribosomal protein L10 Xq28
RPP25 Ribonuclease P/MRP 25 kDa subunit 15q24.2
RPS6KA1 Ribosomal protein S6 kinase, 90 kDa, polypeptide 1 1p36.11
RPS6KA2 Ribosomal protein S6 kinase, 90 kDa, polypeptide 2 6q27
RPS6KA3 Ribosomal protein S6 kinase, 90 kDa, polypeptide 3 Xp22.12
RUVBL1 RuvB-E. coli, homolog-like 1 3q21.3
SAE1 SUMO1 activating enzyme, subunit 1 19q13.32
SATB2 Special AT-rich sequence-binding protein 2 2q33.1
SBF1 SET binding factor 1 22q13.33
SCFD2 Sec1 family domain containing 2 4q12
SCN1A Sodium channel, neuronal, type I, α subunit 2q24.3
SCN2A Sodium channel, voltage-gated, type II, α subunit 2q24.3
SCN7A Sodium channel, voltage-gated, type VII, α subunit 2q24.3
SCN8A Sodium channel, voltage-gated, type VIII, α subunit 12q13.13
SDC2 Syndecan 2 8q22.1
SDK1 Sidekick cell adhesion molecule 1 7p22.2
SEMA3F Sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3F 3p21.31
SEMA5A Semaphorin 5A 5p15.31
SERPINE1 Serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 7q22.1
SETBP1 SET binding protein 1 18q12.3
SETD2 SET domain containing protein 2 3p21.31
SETD5 SET domain containing protein 5 3p25.3
SETDB1 SET domain, bifurcated, 1 1q21.3
SETDB2 SET domain, bifurcated, 2 13q14.2
SEZ6L2 Seizure related 6 homolog (mouse)-like 2 16p11.2
SF1 Splicing factor 1 11q13.1
SFPQ Splicing factor proline/glutamine-rich 1p34.3
SFTPD Surfactant, pulmonary-associated protein D 10q22.3
SGSH N-sulfoglucosamine sulfohydrolase 17q25.3
SGSM3 Small G protein signaling modulator 3 22q13.1
SH3KBP1 SH3-domain kinase binding protein 1 Xp22.12
SHANK1 SH3 and multiple ankyrin repeat domains 1 19q13.3
SHANK2 SH3 and multiple ankyrin repeat domains 2 11q13.4
SHANK3 SH3 and multiple ankyrin repeat domains 3 22q13.33
SLC16A3 Solute carrier family 16 (monocarboxylic acid transporter), member 3 17q25
SLC16A7 Solute carrier family 16 (monocarboxylic acid transporter), member 7 12q14.1
SLC1A1 Solute carrier family 1 (neuronal/epithelial high affinity glutamate transporter), member 1 9p24.2
SLC22A15 Solute carrier family 22, (organic cation transporter), member 15 1p13.1
SLC24A2 Solute carrier family 24 (sodium/potassium/calcium exchanger), member 2 9p22.1
SLC25A12 Solute carrier family 25 (mitochondrial carrier, Aralar), member 12 2q31.1
SLC25A14 Solute carrier family 25 (mitochondrial carrier, brain), member 14 Xq26.1
SLC25A24 Solute carrier family 25 (mitochondrial carrier, phosphate carrier), member 24 1p13.3
SLC25A27 Solute carrier family 25, member 27 6p12.3
SLC29A4 Solute carrier family 29 (equilibrative nucleoside transporter), member 4 7p22.1
SLC30A5 Solute carrier family 30 (zinc transporter), member 5 5q13.1
SLC35A3 Solute carrier family 35 (UDP-N-acetylglucosamine transporter), member 3 1p21.2
SLC38A10 Solute carrier family 38, member 10 17q25.3
SLC39A11 Solute carrier family 39 (metal ion transporter), member 11 17q21.31
SLC4A10 Solute carrier family 4 (sodium bicarbonate transporter-like), member 10 2q24.2
SLC6A1 Solute carrier family 6 (neurotransmitter transporter), member 1 3p25.3
SLC6A3 Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 5p15.33
SLC6A4 Solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 17q11.2
SLC6A8 Solute carrier family 6 (neurotransmitter transporter, creatine), member 8 Xq28
SLC9A6 Solute carrier family 9 (sodium/hydrogen exchanger), member 6 Xq26.3
SLC9A9 Solute carrier family 9 (sodium/hydrogen exchanger), member 9 3q24
SLCO1B1 Solute carrier organic anion transporter family, member 1B1 12p12.2
SLCO1B3 Solute carrier organic anion transporter family, member 1B3 12p12.2
SLIT3 Slit, Drosophila, homolog of, 3 5q35.1
SLITRK5 SLIT and NTRK-like family, member 5 13q31.2
SLK STE20-like kinase 10q24.33
SMAD2 SMAD family member 2 18q21.1
SMARCC2 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily C, member 2 12q13.2
SMG6 SMG 6, C. elegans, homolog of 17p13.3
SND1 EBNA2 coactivator p100 7q32.1
SNRPN Small nuclear ribonucleoprotein polypeptide N 15q11.2
SNTG2 Syntrophin, γ 2 2p25.3
SNX19 Sorting nexin 19 11q25
SNX5 Sorting nexin 5 20p11.23
SOD1 Superoxide dismutase 1, soluble 21q22.11
SOS1 Son of sevenless (SOS), Drosophila, homolog 1 2p22.1
SOX5 SRY (sex determining region Y)-box 5 12p12.1
SOX7 SRY (sex determining region Y)-box 7 8p23.1
SPAST Spastin 2p22.3
SRD5A2 Steroid-5-α-reductase, 2 2p23.1
ST7 Suppressor of tumorigenicity 7 7q31.2
ST8SIA2 ST8 α-N-acetyl-neuraminide α-2,8-sialyltransferase 2 15q26.1
STK39 Serine/threonine protein kinase 39 2q24.3
STX6 Syntaxin 6 1q25.3
STX1A Syntaxin 1A 7q11.23
STXBP1 Syntaxin-binding protein 1 9q34.1
STXBP5 Syntaxin-binding protein 5 6q24.3
STXBP5L Syntaxin-binding protein 5-like 3q13.33
SUCLG2 Succinate-CoA ligase, GDP-forming, β subunit 3p14.1
SUV420H1 Suppressor of variegation 4–20, Drosophila, homolog of, 1 11q13.2
SYAP1 Synapse associated protein 1 Xp22.2
SYN1 Synapsin 1 Xp11.23
SYN2 Synapsin II 3p25.2
SYN3 Synapsin III 22q12.3
SYNE1 Spectrin repeat containing nuclear envelope 1 6q25.2
SYNGAP1 Synaptic RAS-GTPase-activating protein 1 6p21.32
SYT17 Synaptotagmin XVII 16p12.3
SYT3 Synaptotagmin III 19q13.33
TAF1C TATA box-binding protein-associated factor 1C 16q24.1
TAF1L TATA box-binding protein-associated factor 1-like 9p21.1
TAS2R1 Taste receptor, type 2, member 1 5p15.31
TBC1D30 TBC1 domain family, member 30 12q14.3
TBC1D5 TBC1 domain family, member 5 3p24.3
TBC1D7 TBC1 domain family, member 7 6p24
TBL1X Transducin-β-like 1, X-linked Xp22.31
TBL1XR1 Transducin-β-like 1 receptor 1 3q26.32
TBR1 T-box, brain, 1 2q24.2
TBX1 T-box 1 22q11.21
TCF3 Transcription factor 3 19p13.3
TCF4 Transcription factor 4 18q21.2
TCF20 Transcription factor 20 (AR1) 22q13.2
TCF7L2 Transcription factor 7-like 2 (t-cell specific, HMG-box) 10q25.2
TDO2 Tryptophan 2,3-dioxygenase 4q32.1
TGM3 Transglutaminase 3 20p13
TH Tyrosine hydroxylase 11p15.5
THBS1 Thrombospondin 1 15q14
THRA Thyroid hormone receptor, α-1 17q21.1
TLK2 Tousled-like kinase 2 17q23.2
TLX1 T-cell leukemia homeobox 1 10q24.31
TM4SF20 Transmembrane 4 L6 family, member 20 2q36.3
TMEM231 Transmembrane protein 231 16q23.1
TMLHE Epsilon-trimethyllysine hydroxylase Xq28
TNIP2 TNFAIP3 interacting protein 2 4p16.3
TNRC6B Trinucleotide repeat containing 6B 22q13.1
TOMM20 MAS20P, S. cerevisiae, homolog of 1q42.3
TOP1 Topoisomerase, DNA, I 20q12
TOP3B Topoisomerase, DNA, III, β 22q11.22
TOPBP1 Topoisomerase (DNA) II-binding protein 1 3q22.1
TOPORS Topoisomerase I-binding, arginine/serine-rich, E3 ubiquitin protein ligase 9p21.1
TPH2 Tryptophan hydroxylase 2 12q21.1
TPO Thyroid peroxidase 2p25.3
TRIM33 Tripartite motif containing protein 33 1p13.2
TRIO Trio Rho guanine nucleotide exchange factor 5p15.2
TRIP12 Thyroid hormone receptor interactor 12 2q36.3
TRPC6 Transient receptor potential cation channel, subfamily C, member 6 11q22.1
TRPM1 Transient receptor potential cation channel, subfamily M, member 1 15q13.3
TSC1 Tuberous sclerosis 1 9q34.1
TSC2 Tuberous sclerosis 2 16p13.3
TSN Translin 2q14.3
TSPAN7 Tetraspanin 7 Xp11.4
TTI2 TELO2-interacting protein 2 8p12
TTN Titin 2q31.2
TUBA1A Tubulin, α-1A 12q13.12
TUBGCP5 Tubulin-γ complex-associated protein 5 15q11.2
TYR Tyrosinase 11q14.3
UBE1L2 Ubiquitin-activating enzyme, E1-like 2 4q13.2
UBE2H Ubiquitin-conjugating enzyme E2H 7q32.2
UBE3A Ubiquitin protein ligase E3A 15q11.2
UBE3B Ubiquitin protein ligase E3B 12q24.11
UBE3C Ubiquitin protein ligase E3C 7q36.3
UBL7 Ubiquitin-like 7 15q24.1
UBR5 Ubiquitin protein ligase E3 component N-recognin 5 8q22.3
UBR7 Ubiquitin protein ligase E3 component N-recognin 7 14q32.12
UIMC1 Ubiquitin interaction motif containing 1 5q35.2
UPB1 Ureidopropionase, β 1 22q11.23
UPF2 UPF2, yeast, homolog of 10p14
UPF3B UPF3, yeast, homolog of, B Xq24
USP54 Ubiquitin specific peptidase 54 10q22.2
USP9Y Ubiquitin specific protease 9, Y-chromosome Yq11.21
VASH1 Vasohibin 1 14q24.3
VCP Valosin containing protein 9p13.3
VIL1 Villin 1 2q35
VIP Vasoactive intestinal peptide (VIP) 6q25.2
VPS13B Vacuolar protein sorting 13, yeast, homolog of, B 8q22.2
VPS4A Vacuolar protein sorting 4 homolog A (S. cerevisiae) 16q22.1
WAC WW domain containing adaptor with coiled-coil 10p12.1
WDFY3 WD repeat and FYVE domain containing 3 4q21.23
WHSC1 Wolf-Hirschhorn syndrome candidate 1 4p16.3
WNK3 Protein kinase lysine deficient 3 Xp11.22
WNT1 Wingless-type MMTV integration site family, member 1 12q13.12
WNT2 Wingless-type MMTV integration site family, member 2 7q31.2
WWC3 WWC family member 3 Xp22.32
XIRP1 Cardiomyopathy-associated protein 1 3p22.2
XPC Xeroderma pigmentosum complementation group C 3p25.1
XPO1 Exportin 1 2p15
XPO5 Exportin 5 6p21.1
YEATS2 YEATS domain containing 2 3q27.1
YTHDC2 YTH domain containing 2 5q22.2
YWHAE Tyrosine 3-monooxygenase, tryptophan 5-monooxygenase activation protein, epsilon isoform 17p13.3
ZBTB16 Zinc finger- and BTB domain-containing protein 16 11q23.1
ZBTB20 Zinc finger- and BTB domain-containing protein 20 3q13.31
ZC3H12B Zinc finger CCCH domain-containing protein 12B Xq12
ZFPL1 Zinc finger protein-like 1 11q13.1
ZMYND11 Zinc finger, MYND-type containing 11 10p15.3
ZNF18 Zinc finger protein 18 17p12
ZNF365 Zinc finger protein 365 10q21.2
ZNF385B Zinc finger protein 385B 2q31.3
ZNF407 Zinc finger protein 407 18q23
ZNF517 Zinc finger protein 517 8q24.3
ZNF8 Zinc finger protein 8 19q13.43
ZNF713 Zinc finger protein 713 7p11.2
ZNF804A Zinc finger protein 804A 2q32.1
ZNF827 Zinc finger protein 827 4q31.22
ZSWIM5 Zinc finger, SWIM-type containing 5 1p34.1

3. Experimental Section

We used computer-based internet websites and PubMed (https://www.ncbi.nlm.nih.gov/pubmed) to search key words for genetics and autism. This included the integrated catalogue of human genetic studies related to autism found at the Simons Foundation Autism Research Initiative (SFARI) website (https://gene.sfari.org), which currently lists 667 genes reported as of 25 February 2015. This public access initiative is an ongoing curated collection of clinically proven ASD genes supported by clinical and autism experts, medical geneticists and laboratory specialists in the study of autism. This site includes gene description and evidence of support for causation with cited literature reports. We examined peer-reviewed articles found in the medical literature following our search for genetic evidence (i.e., gene variants, mutations or disturbed gene function) and the involvement of genetics playing a role in autism. Sources included whole-genome sequencing of ASD families randomly selected with at least one unaffected sibling [40] or gene expression profiles in ASD [39] along with other informative websites (e.g., Online Mendelian Inheritance in Man, www.OMIM.org). We then compiled the list of genes from these major sources for a total of 792 genes, whereby at least one mechanism was involved for each gene that could lead to ASD, a heterogeneous condition involving many genes; as our report is focused on the compilation of ASD genes from peer-reviewed research articles and authoritative computer website genomic databases for autism and not necessarily related to causal relationships between the individual gene and ASD. Those genes recognized, to date, as playing a role in ASD susceptibility and causation generally appear to impact chromatin remodeling, metabolism, mRNA translation, cell adhesion and synaptic function [39].

SFARI is a publicly available manually curated web-based searchable site of human genes with links to ASD and includes genes in catalogue form based on five categories—genetic association, syndromic, rare single-gene variant and functional and multi-genetic copy number variation—supported by cited research publications for each. Additional literature sources in our study consisted of both primary research articles and reviews summarizing genetic evidence. Many of the listed genes were identified in multiple research studies and widely reported in literature reviews, data repositories and/or computer genomic-based websites for autism (e.g., SFARI). A large number of genes showed a varied relationship to autism and neurodevelopment, but the mass of the literature surveyed limits the reliability of our relative strength estimates for the ASD and gene associations. The gene would be included if cited and recognized in peer-reviewed publications (e.g., PubMed) with supportive genetic evidence (e.g., genetic linkage, GWAS, functional gene expression patterns, informative SNPs, CNVs or identified gene mutations). Other supporting genetic evidence can be found at Simons Foundation Autism Research Initiative (SFARI) at https://sfari.org/sfari-initiatives/simons-simplex-collection, the National Institutes of Health (NIH) at https://www.ncbi.nlm.nih.gov/gap, the Online Inheritance in Man (OMIM) at www.omim.org or Genecards at https://www.genecards.org.

4. Conclusions

Readily available tissue sources, such as peripheral blood, established lymphoblastoid cell lines and saliva, hold promise for more advances in ASD by enabling the identification of new genes and a better understanding of the causation and disease mechanisms to further stimulate research with the hope to discover new treatment modalities impacted by the recognition of known disease-causing or candidate genes for ASD. We illustrated the master list of clinically relevant and known ASD genes in our summary by plotting individual genes on high-resolution chromosome ideograms and generated a tabular form to increase the awareness required for genetic testing and counselling purposes for family members presenting for genetic services. Creating a master list of genes related to ASD is a complicated process; new genes are continually identified, but not all genes are equally important or certain to be causative. Additional research is needed to further investigate the causal relationships between the specific gene and ASD. The authors encourage the use of this collection of known and clinically relevant candidate genes for ASD in their evaluation of patients and families presenting for genetic testing options and for accurate genetic counselling.

Acknowledgments

We thank Carla Meister for expert preparation of the manuscript and Lorie Gavulic for excellent artistic design and preparation of chromosome ideograms. We acknowledge support from National Institute of Child Health and Human Development (NICHD) HD02528.

Author Contributions

Merlin G. Butler conceived of the study, reviewed data from ASD gene literature reports and wrote the manuscript; Syed K. Rafi obtained and reviewed articles pertaining to ASD genes and summarized the master gene list; and Ann M. Manzardo contributed to gene data review and interpretation, contributed to the content of the manuscript and reviewed the literature.

Conflicts of Interest

The authors declare no conflict of interest.

References

  • 1.American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders. 4th ed. American Psychiatric Association; Washington, DC, USA: 2000. [Google Scholar]
  • 2.Johnson C.P., Myers S.M., American Academy of Pediatrics Counsel on Children with Disablities Identifiction and evaluation of children with autism spectrum disorders. Pediatrics. 2007;120:1183–1215. doi: 10.1542/peds.2007-2361. [DOI] [PubMed] [Google Scholar]
  • 3.Hughes J.R. Update on autism: A review of 1300 reports published in 2008. Epilepsy Behav. 2009;16:569–589. doi: 10.1016/j.yebeh.2009.09.023. [DOI] [PubMed] [Google Scholar]
  • 4.Lord C., Risi S., Lambrecht L., Cook E.H., Jr., Leventhal B.L., DiLavore P.C., Pickles A., Rutter M. The autism diagnostic observation schedule-generic: A standard measure of social and communication deficits associated with the spectrum of autism. J. Autism Dev. Disord. 2000;30:205–223. doi: 10.1023/A:1005592401947. [DOI] [PubMed] [Google Scholar]
  • 5.Le Couteur A., Lord C., Rutter M. Autism Diagnostic Interview-Reviewed (ADI-R) Western Psychological Services; Los Angeles, CA, USA: 2003. [Google Scholar]
  • 6.Constantino J.N., Davis S.A., Todd R.D., Schindler M.K., Gross M.M., Brophy S.L., Metzger L.M., Shoushtari C.S., Splinter R., Reich W. Validation of a brief quantitative measure of autistic traits: Comparison of the social responsiveness scale with the autism diagnostic interview-revised. J. Autism Dev. Disord. 2003;33:427–433. doi: 10.1023/A:1025014929212. [DOI] [PubMed] [Google Scholar]
  • 7.Rice C. Prevalence of autism spectrum disorders-autism and developmental disabilities monitoring network, United States, 2006. MMWR Surveill. Summ. 2009;58:3–8. [PubMed] [Google Scholar]
  • 8.Fombonne E. Epidemiology of autistic disorder and other pervasive developmental disorders. J. Clin. Psychiatry. 2005;66(Suppl. 10):3–8. [PubMed] [Google Scholar]
  • 9.Kanner L. Autistic psychopathy in childhood. Nerv. Child. 1943;2:217–250. [Google Scholar]
  • 10.Rapin I. Autistic regression and disintegrative disorder: How important the role of epilepsy? Semin. Pediatr. Neurol. 1995;2:278–285. doi: 10.1016/S1071-9091(95)80007-7. [DOI] [PubMed] [Google Scholar]
  • 11.Geschwind D.H., Levitt P. Autism spectrum disorders: Developmental disconnection syndromes. Curr. Opin. Neurobiol. 2007;17:103–111. doi: 10.1016/j.conb.2007.01.009. [DOI] [PubMed] [Google Scholar]
  • 12.Kurtzke J. Neuroepidemiology. In: Bradley W., Daroff R., Fenichel G., Marsden C., editors. Neurology in Clinical Practice. Butterworth-Heinemann; Stoneham, MA, USA: 1991. pp. 545–560. [Google Scholar]
  • 13.Gadia C.A., Tuchman R., Rotta N.T. Autism and pervasive developmental disorders. J. Pediatr. 2004;80:S83–S94. doi: 10.2223/1172. [DOI] [PubMed] [Google Scholar]
  • 14.Butler M.G., Dasouki M.J., Zhou X.P., Talebizadeh Z., Brown M., Takahashi T.N., Miles J.H., Wang C.H., Stratton R., Pilarski R., et al. Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. J. Med. Genet. 2005;42:318–321. doi: 10.1136/jmg.2004.024646. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Prontera P., Ottaviani V., Toccaceli D., Rogaia D., Ardisia C., Romani R., Stangoni G., Pierini A., Donti E. Recurrent approximately 100 kb microdeletion in the chromosomal region 14q11.2, involving CHD8 gene, is associated with autism and macrocephaly. Am. J. Med. Genet. A. 2014;164:3137–3141. doi: 10.1002/ajmg.a.36741. [DOI] [PubMed] [Google Scholar]
  • 16.Benvenuto A., Moavero R., Alessandrelli R., Manzi B., Curatolo P. Syndromic autism: Causes and pathogenetic pathways. World J. Pediatr. 2009;5:169–176. doi: 10.1007/s12519-009-0033-2. [DOI] [PubMed] [Google Scholar]
  • 17.Holt R., Monaco A.P. Links between genetics and pathophysiology in the autism spectrum disorders. EMBO Mol. Med. 2011;3:438–450. doi: 10.1002/emmm.201100157. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Campbell D.B., Sutcliffe J.S., Ebert P.J., Militerni R., Bravaccio C., Trillo S., Elia M., Schneider C., Melmed R., Sacco R., et al. A genetic variant that disrupts MET transcription is associated with autism. Proc. Natl. Acad. Sci. USA. 2006;103:16834–16839. doi: 10.1073/pnas.0605296103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Schaefer G.B., Starr L., Pickering D., Skar G., Dehaai K., Sanger W.G. Array comparative genomic hybridization findings in a cohort referred for an autism evaluation. J. Child Neurol. 2010;25:1498–1503. doi: 10.1177/0883073810370479. [DOI] [PubMed] [Google Scholar]
  • 20.Roberts J.L., Hovanes K., Dasouki M., Manzardo A.M., Butler M.G. Chromosomal microarray analysis of consecutive individuals with autism spectrum disorders or learning disability presenting for genetic services. Gene. 2014;535:70–78. doi: 10.1016/j.gene.2013.10.020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Butler M.G., Usrey K., Roberts J.L., Schroeder S.R., Manzardo A.M. Clinical presentation and microarray analysis of Peruvian children with atypical development and/or aberrant behavior. Genet. Res. Int. 2014;2014:408516. doi: 10.1155/2014/408516. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Miles J.H. Autism spectrum disorders—A genetics review. Genet. Med. 2011;13:278–294. doi: 10.1097/GIM.0b013e3181ff67ba. [DOI] [PubMed] [Google Scholar]
  • 23.Liu X., Takumi T. Genomic and genetic aspects of autism spectrum disorder. Biochem. Biophys. Res. Commun. 2014;452:244–253. doi: 10.1016/j.bbrc.2014.08.108. [DOI] [PubMed] [Google Scholar]
  • 24.Cox D.M., Butler M.G. The 15q11.2 BP1-BP2 microdeletion syndrome: A review. Int. J. Mol. Sci. 2015;16:4068–4082. doi: 10.3390/ijms16024068. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Hempel M., Rivera Brugues N., Wagenstaller J., Lederer G., Weitensteiner A., Seidel H., Meitinger T., Strom T.M. Microdeletion syndrome 16p11.2-p12.2: Clinical and molecular characterization. Am. J. Med. Genet. A. 2009;149:2106–2112. doi: 10.1002/ajmg.a.33042. [DOI] [PubMed] [Google Scholar]
  • 26.Fernandez B.A., Roberts W., Chung B., Weksberg R., Meyn S., Szatmari P., Joseph-George A.M., Mackay S., Whitten K., Noble B., et al. Phenotypic spectrum associated with de novo and inherited deletions and duplications at 16p11.2 in individuals ascertained for diagnosis of autism spectrum disorder. J. Med. Genet. 2010;47:195–203. doi: 10.1136/jmg.2009.069369. [DOI] [PubMed] [Google Scholar]
  • 27.Miller D.T., Shen Y., Weiss L.A., Korn J., Anselm I., Bridgemohan C., Cox G.F., Dickinson H., Gentile J., Harris D.J., et al. Microdeletion/duplication at 15q13.2q13.3 among individuals with features of autism and other neuropsychiatric disorders. J. Med. Genet. 2009;46:242–248. doi: 10.1136/jmg.2008.059907. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Ritvo E.R., Jorde L.B., Mason-Brothers A., Freeman B.J., Pingree C., Jones M.B., McMahon W.M., Petersen P.B., Jenson W.R., Mo A. The UCLA-university of Utah epidemiologic survey of autism: Recurrence risk estimates and genetic counseling. Am. J. Psychiatry. 1989;146:1032–1036. doi: 10.1176/ajp.146.8.1032. [DOI] [PubMed] [Google Scholar]
  • 29.Sandin S., Lichtenstein P., Kuja-Halkola R., Larsson H., Hultman C.M., Reichenberg A. The familial risk of autism. JAMA. 2014;311:1770–1777. doi: 10.1001/jama.2014.4144. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Sebat J., Lakshmi B., Malhotra D., Troge J., Lese-Martin C., Walsh T., Yamrom B., Yoon S., Krasnitz A., Kendall J., et al. Strong association of de novo copy number mutations with autism. Science. 2007;316:445–449. doi: 10.1126/science.1138659. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Lauritsen M.B., Als T.D., Dahl H.A., Flint T.J., Wang A.G., Vang M., Kruse T.A., Ewald H., Mors O. A genome-wide search for alleles and haplotypes associated with autism and related pervasive developmental disorders on the Faroe islands. Mol. Psychiatry. 2006;11:37–46. doi: 10.1038/sj.mp.4001754. [DOI] [PubMed] [Google Scholar]
  • 32.Ma D., Salyakina D., Jaworski J.M., Konidari I., Whitehead P.L., Andersen A.N., Hoffman J.D., Slifer S.H., Hedges D.J., Cukier H.N., et al. A genome-wide association study of autism reveals a common novel risk locus at 5p14.1. Ann. Hum. Genet. 2009;73:263–273. doi: 10.1111/j.1469-1809.2009.00523.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Weiss L.A., Arking D.E., Gene Discovery Project of Johns Hopkins & the Autism Consortium. Daly M.J., Chakravarti A. A genome-wide linkage and association scan reveals novel loci for autism. Nature. 2009;461:802–808. doi: 10.1038/nature08490. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Anney R., Klei L., Pinto D., Regan R., Conroy J., Magalhaes T.R., Correia C., Abrahams B.S., Sykes N., Pagnamenta A.T., et al. A genome-wide scan for common alleles affecting risk for autism. Hum. Mol. Genet. 2010;19:4072–4082. doi: 10.1093/hmg/ddq307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Wang K., Zhang H., Ma D., Bucan M., Glessner J.T., Abrahams B.S., Salyakina D., Imielinski M., Bradfield J.P., Sleiman P.M., et al. Common genetic variants on 5p14.1 associate with autism spectrum disorders. Nature. 2009;459:528–533. doi: 10.1038/nature07999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Pinto D., Pagnamenta A.T., Klei L., Anney R., Merico D., Regan R., Conroy J., Magalhaes T.R., Correia C., Abrahams B.S., et al. Functional impact of global rare copy number variation in autism spectrum disorders. Nature. 2010;466:368–372. doi: 10.1038/nature09146. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Pagnamenta A.T., Khan H., Walker S., Gerrelli D., Wing K., Bonaglia M.C., Giorda R., Berney T., Mani E., Molteni M., et al. Rare familial 16q21 microdeletions under a linkage peak implicate cadherin 8 (CDH8) in susceptibility to autism and learning disability. J. Med. Genet. 2011;48:48–54. doi: 10.1136/jmg.2010.079426. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Klei L., Sanders S.J., Murtha M.T., Hus V., Lowe J.K., Willsey A.J., Moreno-De-Luca D., Yu T.W., Fombonne E., Geschwind D., et al. Common genetic variants, acting additively, are a major source of risk for autism. Mol. Autism. 2012;3:9. doi: 10.1186/2040-2392-3-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Campbell M.G., Kohane I.S., Kong S.W. Pathway-based outlier method reveals heterogeneous genomic structure of autism in blood transcriptome. BMC Med. Genomics. 2013;6:34. doi: 10.1186/1755-8794-6-34. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Jiang Y.H., Yuen R.K., Jin X., Wang M., Chen N., Wu X., Ju J., Mei J., Shi Y., He M., et al. Detection of clinically relevant genetic variants in autism spectrum disorder by whole-genome sequencing. Am. J. Hum. Genet. 2013;93:249–263. doi: 10.1016/j.ajhg.2013.06.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Huguet G., Ey E., Bourgeron T. The genetic landscapes of autism spectrum disorders. Ann. Rev. Genomics Hum. Genet. 2013;14:191–213. doi: 10.1146/annurev-genom-091212-153431. [DOI] [PubMed] [Google Scholar]
  • 42.Correia C., Oliveira G., Vicente A.M. Protein interaction networks reveal novel autism risk genes within gwas statistical noise. PLoS One. 2014;9:e112399. doi: 10.1371/journal.pone.0112399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Merikangas A.K., Segurado R., Heron E.A., Anney R.J., Paterson A.D., Cook E.H., Pinto D., Scherer S.W., Szatmari P., Gill M., et al. The phenotypic manifestations of rare genic CNVs in autism spectrum disorder. Mol. Psychiatry. 2014 doi: 10.1038/mp.2014.150. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Lossifov I., O’Roak B.J., Sanders S.J., Ronemus M., Krumm N., Levy D., Stessman H.A., Witherspoon K.T., Vives L., Patterson K.E., et al. The contribution of de novo coding mutations to autism spectrum disorder. Nature. 2014;515:216–221. doi: 10.1038/nature13908. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Goldani A.A.S., Downs S.R., Widjaja F., Lawton B., Hendren R.L. Biomarkers in autism. Front. Psychiatry. 2014;5:100. doi: 10.3389/fpsyt.2014.00100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Ch’ng C., Kwok W., Rogic S., Pavlidis P. Meta-analysis of gene expression in autism spectrum disorder. 2015 doi: 10.1002/aur.1475. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Uddin M., Tammimies K., Pellecchia G., Alipanahi B., Hu P., Wang Z., Pinto D., Lau L., Nalpathamkalam T., Marshall C.R., et al. Brain-expressed exons under purifying selection are enriched for de novo mutations in autism spectrum disorder. Nat. Genet. 2014;46:742–747. doi: 10.1038/ng.2980. [DOI] [PubMed] [Google Scholar]
  • 48.De Rubeis S., He X., Goldberg A.P., Poultney C.S., Samocha K., Cicek A.E., Kou Y., Liu L., Fromer M., Walker S., et al. Synaptic, transcriptional and chromatin genes disrupted in autism. Nature. 2014;515:209–215. doi: 10.1038/nature13772. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Hadley D., Wu Z.L., Kao C., Kini A., Mohamed-Hadley A., Thomas K., Vazquez L., Qiu H., Mentch F., Pellegrino R., et al. The impact of the metabotropic glutamate receptor and other gene family interaction networks on autism. Nat. Commun. 2014 doi: 10.1038/ncomms5074. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Butler M.G., Rafi S.K., Hossain W., Stephan D.A., Manzardo A.M. Whole exome sequencing in females with autism implicates novel and candidate genes. Int. J. Mol. Sci. 2015;16:1312–1335. doi: 10.3390/ijms16011312. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Yuen R.K., Thiruvahindrapuram B., Merico D., Walker S., Tammimies K., Hoang N., Chrysler C., Nalpathamkalam T., Pellecchia G., Liu Y., et al. Whole-genome sequencing of quartet families with autism spectrum disorder. Nat. Med. 2015;21:185–191. doi: 10.1038/nm.3792. [DOI] [PubMed] [Google Scholar]
  • 52.Willsey J.A., State M.W. Autism spectrum disorders: From genes to neurobiology. Curr. Opin. Neurobiol. 2015;30:92–99. doi: 10.1016/j.conb.2014.10.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Hormozdiari F., Penn O., Borenstein E., Eichler E.E. The discovery of integrated gene networks for autism and related disorders. Genome Res. 2015;25:142–154. doi: 10.1101/gr.178855.114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Butler M.G., Youngs E.L., Roberts J.L., Hellings J.A. Assessment and treatment in autism spectrum disorders: A focus on genetics and psychiatry. Autism Res. Treat. 2012 doi: 10.1155/2012/242537. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Herman G.E., Henninger N., Ratliff-Schaub K., Pastore M., Fitzgerald S., McBride K.L. Genetic testing in autism: How much is enough? Genet. Med. 2007;9:268–274. doi: 10.1097/GIM.0b013e31804d683b. [DOI] [PubMed] [Google Scholar]
  • 56.Butler M.G. Prader-willi syndrome: Obesity due to genomic imprinting. Curr. Genomics. 2011;12:204–215. doi: 10.2174/138920211795677877. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Dhillon S., Hellings J.A., Butler M.G. Genetics and mitochondrial abnormalities in autism spectrum disorders: A review. Curr. Genomics. 2011;12:322–332. doi: 10.2174/138920211796429745. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from International Journal of Molecular Sciences are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)

RESOURCES